The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD)

The Effect of High-Volume Walking With Visual Cues on Gait in People With Parkinson´s Disease. A Randomized Controlled Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01391741

Enrollment

Registered

2011-07-12

Start date

2008-04-30

Completion date

2008-09-30

Last updated

2011-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson´s Disease

Keywords

Parkinson´s Disease, Walking, Exercise, Automaticity, Dual Task, Visual Cues, Cueing, Neuroplasticity, Gait analysis

Brief summary

People with disease (PD) tend to walk with short steps, decreased velocity, and increased stride time variability. Short steps and increased variability are related to greater fall risk. In addition, concurrent performance of a cognitive task (dual-task (DT)) has marked effects on gait in people with PD which is considered to reflect an impaired automaticity of gait. Objective: To investigate short and long term effects of high-volume walking with visual spatial cues (VSC) on gait variables, automaticity, and functional mobility, in people with Parkinson´s Disease (PD), compared with walking without VSC.

Interventions

OTHERVisual Cues

Walking with visual cues for 30 minutes, 4 times a week for 4 weeks

OTHERWalking without visual cues

Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

No minimum to 79 Years

Healthy volunteers

Inclusion criteria

* a confirmed diagnosis of PD according to the UK Parkinson´s Disease Society Brain Bank Clinical Diagnostic Criteria (18) * \<80 years of age * community residing * Hoehn and Yahr (HY) stage 2-3 * Mini Mental State Examination (MMSE) score of \>23 * ability to walk without walking aids for a total of 20 minutes over a 30-minute period

Exclusion criteria

* major modifications of Parkinson´s medication (Madopar \>200 mg/d or \>20% increase in Dopamine agonists) 3 weeks prior to baseline assessment * comorbidities or disabilities, which might influence walking * a history of brain surgery

Design outcomes

Primary

Measure	Time frame
Change in Step Length	Before, after and 3 months after a 4 week training period
Change in Gait Velocity	Before, after and 3 months after a 4 week training period
Change in Stride Time Variability	Before, after and 3 months after a 4 week training period

Secondary

Measure	Time frame
Change in Timed Up & Go (seconds)	Before, after and 3 months after a 4 week training period

Countries

Iceland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026